Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: Potential role of a veto mechanism

Blood

Volumn 88, Issue 3, 1996, Pages 962-969

  Martin, Paul J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0029745548     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.962.962     Document Type: Article

References (41)

1. Martin PJ, Kernan N: T cell depletion for GVHD prevention in humans, in Burakoff S, Deeg JJ, Ferrara J, Atkinson K (eds): Graft Versus Host Disease: Research and Clinical Management, New York, NY, Dekker, 1990, p 371
2. Murphy WJ, Kumar V, Cope JC, Bennett M: An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. J Immunol 144:3305, 1990
3. Martin PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 178:703, 1993
4. Ledbetter JA, Herzenberg LA: Xenogenic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 47:63, 1979
5. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW: Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 131:2178, 1983
6. Sarmiento M, Glasebrook AL, Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing LYT2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980
7. Young JW, Steinman RM: Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med 171:1315, 1990
8. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA: Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374, 1987
9. Bruce J, Symington FW, McKearn TJ, Sprent J: A monoclonal antibody discriminating between subsets of T and B cells. J Immunol 127:2496, 1981
10. Koo GC, Peppard JR: Establishment of monoclonal anti-NK1.1 antibody. Hybridoma 3:301, 1984
11. Ozato K, Mayer N, Sachs DH: Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation 34:113, 1982
12. Ozato K, Mayer N, Sachs DH: Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol 124:533, 1980
13. Shen FW: Monoclonal antibodies to mouse lymphocyte differentiation antigens, in Hammerling GJ, Hammerling U, Kearney JF (eds): Monoclonal Antibodies and T Cell Hybridomas: Perspectives and Technical Advances, Amsterdam, The Netherlands, Elsevier/North Holland and Biomedical Press, 1981, p 25
14. Fink PJ: Veto Cells. Ann Rev Immunol 6:115, 1988
15. Rammensee HG: Veto function in vitro and in vivo. Intern Rev Immunol 4:175, 1989
16. Takeda K, Moore MW, Dennert G: Acute rejection of marrow grafts in mice. Dependence on and independence of functional TCR in the rejection process. J Immunol 152:4407, 1994
17. Takeda K, Dennert G: Demonstration of MHC class I-specific cytolytic activity in IL-2-activated NK1+CD3+ cells and evidence of usage of T and NK cell receptors. Transplantation 58:496, 1994
18. Rembecki RM, Kumar V, David CS, Bennett M: Polymorphism of Hh-1, the mouse hemopoietic histocompatibility locus. Immunogenetics 28:158, 1988
19. Lapidot T, Lubin I, Terenzi A, Faktorowich Y, Erlich P, Reisner Y: Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci USA 87:4595, 1990
20. Faktorowich Y, Lapidot T, Lubin I, Reisner Y: Enhancement of BM allografting from C57BL/6 'nude' mice into C3H/HeJ recipients by tolerized T cells from (C57BL/6 → C3H/HeJ) and (C3H/ HeJ → C57BL/6) chimeras. Bone Marrow Transplant 12:15, 1993
21. Sykes M, Sheard M, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol 141:2282, 1988
22. Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH: Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. J Immunol 143:3503, 1989
23. Azuma E, Kaplan J: Role of lymphokine-activated killer cells as mediators of veto and natural suppression. J Immunol 141:2601, 1988
24. Nakamura H, Gress RE: Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo. Transplantation 49:931, 1990
25. Murphy WJ, Bennett M, Kumar V, Longo DL: Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 148:2953, 1992
26. Murphy WJ, Keller JR, Harrison CL, Young HA, Longo DL: Interleukin-1-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80:670, 1992
27. Hiruma K, Nakamura H, Henkart PA, Gress RE: Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes. J Exp Med 175:863, 1992
28. Hiruma K, Gress RE: Cyclosporine A and peripheral tolerance. Inhibition of veto cell-mediated clonal deletion of postthymic precursor cytotoxic T lymphocytes. J Immunol 149:1539, 1992
29. Kiziroglu F, Miller RG: In vivo functional clonal deletion of recipient CD4+ T helper precursor cells that can recognize class II MHC on injected donor lymphoid cells. J Immunol 146:1104, 1991
30. Sambhara SR, Miller RG: Programmed cell death of T cells signaled by the T cell receptor and the α3 domain of class I MHC. Science 252:1424, 1991
31. Salter RD, Benjamin RJ, Wesley PK, Buxton SE, Garrett TP, Clayberger C, Krensky AM, Norment AM, Littman DR, Parham P: A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 345:41, 1990
32. Cassell D, Forman J: Two roles for CD4 cells in the control of the generation of cytotoxic T lymphocytes. J Immunol 146:3, 1991
33. Pierce GE: Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity. Transplantation 49:138, 1990
34. Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler H, Mueller-Ruchholtz W: Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 79:1612, 1992
35. Martin DR, Miller RG: In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J Exp Med 170:679, 1989
36. Rammensee HG, Fink PJ, Bevan MJ: The veto concept: An economic system for maintaining self tolerance of cytotoxic T lymphocytes. Transplant Proc 17:689, 1985
37. Sondel PM, Hank JA, Trigg ME, Kohler PC, Finlay JL, Blank J, Meisner L, Borcherding W, Hong R, Steves R, Billing R, Flynn B, Bozdech MJ: Transplantation of HLA-haploidentical T cell-depleted marrow for leukemia: Autologous marrow recovery with specific immune sensitization to donor antigens. Exp Hematol 14:278, 1986
38. Bunjes D, Heit W, Arnold R, Schmeiser T, Weisneth M, Carbonell R, Parzsolt R, Raghauacher A, Heimpel H: Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation 43:501, 1987
39. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ: Graft rejection in recipients of T-cell depleted HLA-nonidentical marrow transplants for leukemia. Transplantation 43:842, 1987
40. Donohue J, Homge M, Kernan NA: Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood 82:1023, 1993
41. Oshima S, Eckels DD: Selective expression of class II MHC isotypes by MLC-activated human T lymphocytes. Hum Immunol 27:208, 1990